Generali Investments Management Co LLC Purchases New Shares in Neurocrine Biosciences, Inc. $NBIX

Generali Investments Management Co LLC acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 2,543 shares of the company’s stock, valued at approximately $319,000.

A number of other institutional investors also recently modified their holdings of the business. Dodge & Cox increased its position in Neurocrine Biosciences by 83.5% during the first quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock worth $612,129,000 after acquiring an additional 2,518,199 shares during the period. Los Angeles Capital Management LLC boosted its holdings in Neurocrine Biosciences by 19,454.9% in the 2nd quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock valued at $93,595,000 after purchasing an additional 740,842 shares during the period. Wellington Management Group LLP grew its position in shares of Neurocrine Biosciences by 44.0% during the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock worth $232,037,000 after purchasing an additional 640,556 shares in the last quarter. Swedbank AB increased its holdings in shares of Neurocrine Biosciences by 5,078.9% during the first quarter. Swedbank AB now owns 429,697 shares of the company’s stock worth $47,524,000 after purchasing an additional 421,400 shares during the period. Finally, Braidwell LP raised its position in shares of Neurocrine Biosciences by 32.2% in the first quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock valued at $131,827,000 after buying an additional 290,135 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on NBIX. Truist Financial reissued a “buy” rating and set a $172.00 price target (up previously from $165.00) on shares of Neurocrine Biosciences in a research report on Thursday, October 30th. Needham & Company LLC upped their target price on Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Stifel Nicolaus raised their price target on Neurocrine Biosciences from $174.00 to $183.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $171.00 to $179.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Finally, Guggenheim increased their price objective on shares of Neurocrine Biosciences from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $170.53.

Insider Transactions at Neurocrine Biosciences

In other news, CEO Kyle Gano sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares of the company’s stock, valued at $19,933,581.79. This represents a 0.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director William H. Rastetter sold 18,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the sale, the director owned 40,360 shares in the company, valued at approximately $6,127,455.20. This represents a 30.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.80% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $144.86 on Friday. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $157.67. The company has a market cap of $14.44 billion, a price-to-earnings ratio of 34.66, a PEG ratio of 0.94 and a beta of 0.22. The firm has a 50 day simple moving average of $142.64 and a 200 day simple moving average of $132.86.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same period in the prior year, the business earned $1.81 earnings per share. The company’s revenue for the quarter was up 27.8% compared to the same quarter last year. As a group, analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.